Trial Profile
A prospective, non-intervention real world study of Apatinib in the treatment of advanced lungsquamous carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Liver metastases; Lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2017 Status changed from not yet recruiting to recruiting.
- 29 Aug 2017 New trial record